Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The SWITCH Trial: Apixaban vs Warfarin in HeartMate 3 LVAD Patients
NCT07471139Phase 3Recruiting
- Sponsor
- Columbia University
- Start
- Oct 2026
- Primary completion
- Aug 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of apixaban in thrombosis, hemorrhage, sponsored by Columbia University. Started Oct 2026; status: recruiting.
02
Drugs
apixaban
03
Conditions
thrombosishemorrhage
Beyond the preview
Go deeper on NCT07471139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07471139.